Levi & Korsinsky announces it has commenced an investigation of Tesaro, Inc. (NASDAQ: TSRO) concerning possible violations of federal securities laws.

On January 12, 2018, Tesaro announced it had updated the U.S. labeling of VARUBI® (rolapitant) injectable emulsion packages after reports that some patients receiving the treatment experienced “Anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions.” To obtain additional information, go to:

http://www.zlkdocs.com/TSRO-Info-Request-Form-6373

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.